Efinopegdutide
- Generic Name
- Efinopegdutide
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2055640-93-0
- Unique Ingredient Identifier
- DR6P1M58PO
- Background
Efinopegdutide is under investigation in clinical trial NCT03606057 (A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015)
- Conditions
- Interventions
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 48
- Registration Number
- NCT06701305
- Locations
- πΊπΈ
QPS-MRA, LLC (Site 0001), South Miami, Florida, United States
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
- Conditions
- Interventions
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 129
- Registration Number
- NCT06482112
- Locations
- πΊπΈ
Gastroenterology and Liver Institute ( Site 0263), Escondido, California, United States
πΊπΈExcel Medical Clinical Trials ( Site 0268), Boca Raton, Florida, United States
πΊπΈNeoclinical Research ( Site 0275), Hialeah, Florida, United States
A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)
- Conditions
- Interventions
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 22
- Registration Number
- NCT06052566
- Locations
- πΊπΈ
Clinical Pharmacology of Miami ( Site 0005), Miami, Florida, United States
πΊπΈAmerican Research Corporation ( Site 0002), San Antonio, Texas, United States
πΊπΈAdvanced Pharma CR, LLC ( Site 0001), Miami, Florida, United States
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
- Conditions
- Interventions
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 360
- Registration Number
- NCT05877547
- Locations
- πΊπΈ
Indago Research & Health Center, Inc ( Site 3207), Hialeah, Florida, United States
πΊπΈSweet Hope Research Specialty, Inc-Research ( Site 3200), Hialeah, Florida, United States
πΊπΈVelocity Clinical Research, Syracuse ( Site 3227), East Syracuse, New York, United States
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Subcutaneous (SC) Injections of JNJ-64565111 in Healthy Male Japanese Participants and to Assess Pharmacokinetics Following Subcutaneous Injections of JNJ-64565111 in Healthy Male Caucasian Participants
- First Posted Date
- 2018-08-07
- Last Posted Date
- 2019-08-16
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 42
- Registration Number
- NCT03618160
- Locations
- π―π΅
Souseikai Hakata Clinic, Fukuoka, Japan
π―π΅Sumida Hospital, Tokyo, Japan
A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)
- Conditions
- Interventions
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 188
- Registration Number
- NCT03606057
- Locations
- πΊπΈ
Celerion, Tempe, Arizona, United States
A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 52
- Registration Number
- NCT03586843
- Locations
- πΊπΈ
Celerion, Tempe, Arizona, United States
A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal Function
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT03546205
- Locations
- πΊπΈ
AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company, Knoxville, Tennessee, United States
πΊπΈOrlando Clinical Research Center, Orlando, Florida, United States
A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 39
- Registration Number
- NCT03235219
- Locations
- πΊπΈ
Advanced Pharma CR, LLC, Miami, Florida, United States
πΊπΈProSciento, Inc., Chula Vista, California, United States
Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT02862431
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.